Recombinant antibodies for flow cytometry applications

Flow cytometry is in their genes

REAfinity Antibodies are recombinant antibodies that provide superior lot-to-lot consistency and purity compared to mouse or rat hybridoma-derived, monoclonal antibodies. They have been recombinantly engineered to produce highly specific antibodies that require no FcR blocking step. Additionally, they all have the same IgG1 isotype, requiring less isotype controls.

The manufacturing process of REAfinity Recombinant Antibodies ensures high performance consistency based on the following aspects:

• They are derived from a defined DNA sequence, which encodes only one type of heavy and light chain, ensuring high antibody purity.

• Production under biologically and chemically defined, standardized culture conditions in mammalian cells, resulting in high lot-to-lot consistency.

• Analytical, biochemical, and cell-based testing of every manufactured lot.

All REAfinity Recombinant Antibody clones contain the same specifically mutated human IgG1 sequence as their constant region. This offers the possibility to work with only one type of isotype control, reducing the complexity of experiment planning and saving time.

Hybridoma-derived monoclonal antibodies on the other hand, are composed of antibody isotypes derived from different species and therefore require multiple isotype controls. This complicates not only the management of reagent inventory, but also panel design when setting up experiments.

REAfinity Recombinant Antibodies are designed with flow cytometry in mind. The following properties ensure their superior performance as compared to traditional hybridoma-derived monoclonal antibodies:

• Greater purity

• No background signal

• Highly optimized and standardized fluorochrome conjugation process

All REAfinity Recombinant Antibodies contain a specifically mutated human IgG1 Fc region that abolishes their binding to Fcγ receptors. This allows for background-free analysis and eliminates the need for additional blocking steps such as using a FcR blocking reagent.